CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 941 enrolled
Drug / intervention
Convalescent Plasma +1 morebiological
Likely dose
Convalescent Plasma 2 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04364737
NCT04364737Phase 2Completed
CompareCT.gov

CONTAIN COVID-19: Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients

NYU Langone Health·interventional·Posted Apr 28, 2020·Updated Jan 26, 2023

In Brief

A Phase 2 clinical trial evaluating Convalescent Plasma and Saline solution for COVID-19 and 2 related conditions. Completed, enrolled 941 participants across 9 sites.

Detailed Summary

This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Coronavirus, Coronavirus Infection
CountriesUnited States
CollaboratorsNational Center for Advancing Translational Sciences (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of Miami

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 28, 2020
Enrollment StartApr 17, 2020
Primary CompletionMar 29, 2021
Study CompletionDec 12, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.2 years ago

Interventions

Convalescent Plasmabiological

SARS-CoV-2 convalescent plasma (1-2 units; \~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate

Saline solutionother

Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.